#For patients
Written for adults considering a peptide as part of their health management.
Surgery vs semaglutide and tirzepatide
A 44,025-person record study associated bariatric surgery with more weight loss than semaglutide or tirzepatide, but it was not randomized.
Tirzepatide response after eight weeks
A SURMOUNT post hoc analysis linked early tirzepatide weight response with larger 72-week changes, while later responders still lost weight.
Tirzepatide and lithium safety signal
A 23-person cohort found a lithium safety signal after tirzepatide initiation in bipolar disorder. It cannot estimate the risk or prove causation.
Adolescent GLP-1 use: what remains unknown
A 2026 commentary reviews skeletal, reproductive and psychosocial questions around semaglutide and other GLP-1 drugs in adolescents.
GLP-1 rodent tumor evidence reassessed
A 2026 review argues that GLP-1 rodent thyroid tumors reflect a human-irrelevant mechanism, but long-term human risk is not settled.
Hypothalamic Obesity in Craniopharyngioma
A 2026 review found different obesity patterns after pediatric and adult craniopharyngioma, while direct age comparisons remain absent.
Semaglutide and a thyroid cancer case
A papillary thyroid cancer case during semaglutide use cannot establish causation, and larger human studies have not confirmed excess risk.
Semaglutide and retinal vascular events
A scoping review found more retinal vascular events reported with semaglutide than placebo, but the events were rare and estimates remain uncertain.
Missed Doses of Oral vs Weekly Semaglutide
A Novo Nordisk research letter models what missing doses does to drug levels for oral semaglutide versus once-weekly GLP-1 injections.
Semaglutide in Children: England's Data
A corrected conference abstract from 35 English specialist clinics reports how 406 children and young people fared on semaglutide.
GLP-1 drugs and hidradenitis suppurativa
A new review asks whether semaglutide and other GLP-1 drugs could help hidradenitis suppurativa. The evidence is early, and this is not an approved use.
Oral semaglutide 25 mg vs the injection
A Novo Nordisk funded indirect comparison put oral semaglutide 25 mg against the 2.4 mg injection. The weight-loss gap was about one percentage point.